Wall Street analysts predict that Karyopharm Therapeutics (NASDAQ:KPTI) will post sales of $4.59 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Karyopharm Therapeutics’ earnings, with the lowest sales estimate coming in at $50,000.00 and the highest estimate coming in at $15.00 million. Karyopharm Therapeutics posted sales of $70,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 6,457.1%. The firm is scheduled to issue its next earnings results on Thursday, May 3rd.
On average, analysts expect that Karyopharm Therapeutics will report full year sales of $13.98 million for the current year, with estimates ranging from $200,000.00 to $30.00 million. For the next year, analysts forecast that the company will report sales of $19.50 million per share, with estimates ranging from $6.61 million to $45.41 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, March 15th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.14). The business had revenue of $1.53 million during the quarter, compared to analyst estimates of $2.26 million. During the same quarter last year, the business earned ($0.65) earnings per share. The company’s quarterly revenue was up 3163.8% on a year-over-year basis.
KPTI has been the topic of several analyst reports. BidaskClub raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, January 25th. ValuEngine raised Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 8th. Royal Bank of Canada reissued a “buy” rating and issued a $22.00 target price on shares of Karyopharm Therapeutics in a report on Friday, March 2nd. Finally, Canaccord Genuity upped their price target on Karyopharm Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, March 12th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $20.20.
In other news, Director Mansoor Raza Mirza sold 2,500 shares of the company’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $17.01, for a total transaction of $42,525.00. Following the transaction, the director now directly owns 2,500 shares of the company’s stock, valued at $42,525. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael Kauffman sold 10,000 shares of the company’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $10.09, for a total value of $100,900.00. Following the transaction, the chief executive officer now directly owns 522,143 shares in the company, valued at $5,268,422.87. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,000 shares of company stock worth $952,625. Corporate insiders own 14.71% of the company’s stock.
Large investors have recently made changes to their positions in the company. Teacher Retirement System of Texas bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $115,000. MetLife Investment Advisors LLC bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $146,000. Two Sigma Investments LP lifted its holdings in Karyopharm Therapeutics by 76.8% in the fourth quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock valued at $233,000 after acquiring an additional 10,520 shares during the period. Wells Fargo & Company MN lifted its holdings in Karyopharm Therapeutics by 18.8% in the fourth quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock valued at $298,000 after acquiring an additional 4,902 shares during the period. Finally, Virtus Fund Advisers LLC bought a new position in Karyopharm Therapeutics in the fourth quarter valued at about $355,000. 62.45% of the stock is currently owned by hedge funds and other institutional investors.
Karyopharm Therapeutics stock opened at $15.13 on Wednesday. Karyopharm Therapeutics has a 12 month low of $7.48 and a 12 month high of $18.00. The firm has a market capitalization of $690.17, a price-to-earnings ratio of -5.38 and a beta of 3.61.
ILLEGAL ACTIVITY NOTICE: This news story was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/04/18/4-59-million-in-sales-expected-for-karyopharm-therapeutics-kpti-this-quarter.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.